Stifel cuts Leidos stock price target on VA contract uncertainty
Stifel reduced its price target for Leidos Holdings (LDOS) to $138 from $142, citing VA contract uncertainty. LDOS reported mixed Q3 2026 results, with revenue missing estimates but EPS and margins beating them. Organic revenue grew 0.6% YoY, led by the Homeland segment, while the Health segment declined 11.7%. The company's book-to-bill ratio was 1.2x, with the Defense segment at 1.9x. Management expects no earnings growth in 2027 due to VA contract delays.
How this was made
The 30-second read
Why it matters
Stifel's target cut reflects heightened risk from VA contract delays, likely pressuring the stock.
Market read
Analyst downgrade adds fresh downside pressure to LDOS after earnings release.
What to watch
Health segment decline and book‑to‑bill strength in Defense may offset short‑term concerns.
Background
Leidos reported mixed Q3 2026 results with revenue miss but earnings beat, prompting analyst revisions.
Ticker impact
Stifel cut Leidos price target to $138, citing VA contract uncertainty after mixed Q3 results.
likely downward pressure as the market prices in the lower target
Target reduction and highlighted contract risk suggest earnings reset, prompting short-term downside.
Market effects
Defense sector may see broader scrutiny of VA contract pipelines.
U.S. defense stocks could face modest pullback.
Limited to U.S. equities; no immediate global ripple.
Counterpoint
Guggenheim maintains a $160 target, indicating potential upside if defense programs accelerate.
Key entities
- companyLeidos Holdings
U.S. defense and health technology contractor.
- analystStifel
Equity research firm issuing the price target revision.
